Curanex Pharmaceuticals Stock Soars 56.32% After Key IND Milestone

Written by Emily J. Thompson, Senior Investment Analyst

Source: Benzinga

Updated: Feb 26 2026

0mins

CURX-3.27%

Should l Buy CURX?

Source: Benzinga

Key Milestone Achieved: Curanex Pharmaceuticals announced the completion of a GMP-compliant pilot-scale batch of its lead botanical drug candidate, Phyto-N, driving a 56.32% increase in after-hours trading to $0.49, reflecting strong market confidence in its future potential.
IND Submission Plans: The company aims to submit an Investigational New Drug application for ulcerative colitis, affecting approximately 5 million patients globally, targeted for the fourth quarter of 2026, indicating a strategic focus in the chronic inflammatory bowel disease sector.
Clinical Research Advancement: CEO Jun Liu stated that GLP toxicology and pharmacokinetic studies are underway, with clinical trials planned in Australia to further validate the drug's safety and efficacy, showcasing the company's commitment to advancing its pipeline.
Market Performance Analysis: Despite a market capitalization of $8.73 million and a 92.15% decline in stock price over the past 12 months, recent positive developments may present potential rebound opportunities for investors, necessitating close monitoring for signs of recovery.

Trade with 70% Backtested Accuracy

Stop guessing "Should I Buy CURX?" and start using high-conviction signals backed by rigorous historical data.

Analyst Views on CURX

About CURX

Curanex Pharmaceuticals Inc is a developmental stage pharmaceutical company. The Company is engaged in discovering, developing, and commercializing botanical drugs to treat patients suffering from inflammatory diseases and to develop therapies that offer potential benefits to patients with unmet clinical needs in various fields, such as autoimmune diseases, metabolic diseases and viral infections. Its lead candidate, Phyto-N, is a botanical extract from a single plant with anti-inflammatory properties that act via multiple targets and mechanisms. Its drug development pipelines encompass six various therapeutic areas: ulcerative colitis, atopic dermatitis, COVID-19, diabetes, NAFLD, and gout. Phyto-N is being developed as an orally administered alternative for patients with moderate to severe ulcerative colitis, aiming to address limitations of current treatments. The Company's two botanical drugs include Veregen (sinecatechins) and Fulyzaq/Mytesi (crofelemer).

About the author

Emily J. Thompson

Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.

Curanex Pharmaceuticals Stock Rises 6% on Positive Patient Case Study for Phyto-N

Apr 06 2026NASDAQ.COM

Patient Case Study: Curanex Pharmaceuticals Inc. highlighted a compelling case involving a pancreatic neuroendocrine tumor patient, demonstrating significant improvements after one month on Phyto-N, including increased energy, abdominal pain resolution, and normalized complexion, underscoring the product's potential efficacy.
Biomarker Improvements: Laboratory tests confirmed that the patient's serum amylase, lipase, and triglycerides returned to normal ranges, indicating Phyto-N's positive impact on physiological conditions, which could offer new treatment options for cancer patients.
Market Opportunity: Curanex views cancer cachexia as a multi-billion-dollar market opportunity, with no FDA-approved therapies currently available; Phyto-N is positioned to play a crucial role in enhancing quality of life and maintaining cancer treatment, as emphasized by CEO Jun Liu.
Future Development Plans: Curanex is advancing Phyto-N through preclinical studies in preparation for an IND submission for ulcerative colitis in 2026, while also exploring broader supportive care opportunities in oncology, reflecting the company's strategic focus on future market potential.

Curanex Highlights Potential of Phyto-N in Cancer Cachexia Treatment

Apr 06 2026Newsfilter

Patient Case Study: Curanex Pharmaceuticals highlights a patient case from Memorial Sloan Kettering Cancer Center, demonstrating the potential efficacy of its drug Phyto-N in cancer cachexia, with the patient reporting significant improvements in energy and quality of life within one month of use.
Biomarker Improvement: Following Phyto-N treatment, laboratory tests indicated substantial improvements in pancreatic biomarkers, with serum amylase decreasing from 191 to 90 and serum lipase from 298 to 52, both returning to normal ranges, suggesting a positive impact on cancer-related cachexia.
Market Demand and Strategic Significance: Cancer cachexia affects up to 80% of advanced cancer patients, and Curanex believes that therapies aiding in weight maintenance and quality of life are clinically significant, especially given the lack of effective treatment options currently available.
Future Development Focus: Curanex is expanding its strategic focus to include cancer cachexia treatment, with plans for an Investigational New Drug submission in Q4 2026, reflecting the company's commitment to addressing this significant unmet medical need.

Curanex Pharmaceuticals Advances Key Milestones, Plans IND Submission

Mar 30 2026Newsfilter

Manufacturing Capability Enhancement: Curanex advanced key chemistry, manufacturing, and controls (CMC) activities for Phyto-N in 2025 and early 2026, including optimizing production processes and completing a GMP-compliant pilot batch, which is expected to significantly accelerate the clinical development process for the IND submission.
Toxicology Study Breakthrough: The company completed a dose-range finding toxicology study in rats and dogs, confirming the maximum feasible dose with no significant adverse reactions, providing crucial data for the upcoming GLP toxicology study design, marking an important step toward the IND submission.
Clear Regulatory Pathway: Curanex plans to submit its first IND application for ulcerative colitis in Q4 2026 and initiate Phase 1 clinical development in Australia in the same quarter, which is expected to support the company's position in the $8.17 billion market.
Intellectual Property Expansion: The company filed a Patent Cooperation Treaty (PCT) application in March 2025 covering autoimmune diseases, metabolic diseases, and viral infections, enhancing the long-term strategic value of its core therapeutic assets and solidifying its position in multi-indication drug development.

U.S. Stocks Mostly Lower in Morning Trading

Feb 26 2026Benzinga

Market Performance: U.S. stocks traded mostly lower this morning, with the Nasdaq Composite dropping over 350 points, and the S&P 500 falling 0.88% to 6,884.75, indicating a weakening market sentiment that could impact investor confidence.
Jobless Claims: Initial jobless claims in the U.S. rose by 4,000 to 212,000 during the third week of February, compared to market estimates of 215,000, suggesting ongoing pressures in the labor market that may affect economic recovery.
Sector Performance: Financial shares gained 1.2% on Thursday, while information technology stocks fell by 2.2%, highlighting a divergence among sectors that could lead investors to reassess their investment strategies.
Commodity Market Dynamics: Oil prices increased by 0.5% to $65.76, while gold and silver prices fell by 0.9% and 4.6%, respectively, reflecting a shift in market preference towards risk assets that may influence future investment decisions.

Marriott Vacations Reports Strong Q4, Shares Surge

Feb 26 2026Benzinga

Earnings Beat: Marriott Vacations reported an adjusted EPS of $1.86 for Q4, surpassing market expectations of $1.57, which highlights the company's strong profitability and boosts investor confidence.
Sales Growth: The company's quarterly sales reached $1.323 billion, exceeding the anticipated $1.294 billion, indicating sustained competitiveness in the market and enhancing shareholder value.
Stock Surge: In pre-market trading, Marriott Vacations shares jumped 12.7% to $65.34, reflecting market optimism about the company's future growth potential and likely attracting more investor interest.
Positive Guidance: The company also issued FY26 adjusted EPS guidance above estimates, further solidifying its leadership position in the vacation industry and laying a strong foundation for future growth.